# Graves Disease

Confirm Graves disease with TSH-receptor antibodies or characteristic diffuse uptake, distinguish it from destructive and nodular thyrotoxicosis, control adrenergic symptoms, then select antithyroid drugs, radioactive iodine, or thyroidectomy according to reproductive plans, orbitopathy, relapse risk, and treatment goals.

**Clinical question:** How should clinicians confirm Graves disease and select definitive or long-term therapy while accounting for orbitopathy and pregnancy?

Updated: 2026-08-24T17:22:03.237316+00:00

## What matters in practice
- Use a sensitive serum TSH assay as the initial screening test; suppressed TSH with elevated free thyroid hormones establishes overt thyrotoxicosis but not its cause. [8][23]
- Confirm Graves disease with TRAb/TSI when possible; when etiology remains uncertain, thyroid scintigraphy separates diffuse Graves uptake from focal or heterogeneous autonomy and low-uptake hormone release or exogenous hormone exposure. [13][20][23][24]
- A suppressed TSH, normal free T4, and elevated free T3 is T3 thyrotoxicosis, not subclinical hyperthyroidism; toxic nodular goiter and early Graves disease are principal considerations. [23]
- Methimazole, radioactive iodine, and thyroidectomy are established Graves disease treatments; antithyroid drugs are associated with relapse, while long-term treatment beyond 24 months is an alternative for selected patients with persistent TRAb elevation. [8][11][12]
- Active moderate-to-severe Graves orbitopathy changes treatment selection: ATA/ETA consensus emphasizes teprotumumab, particularly for exophthalmos-predominant disease, whereas EUGOGO prioritizes intravenous glucocorticoids with or without mycophenolate. [6]
- During pregnancy, Graves disease may improve in the second and third trimesters; titrate antithyroid therapy frequently and consider dose reduction or discontinuation when disease control permits. [2][16]

## Confirm biochemical thyrotoxicosis before assigning Graves disease

The immediate task is to distinguish increased hormone synthesis from hormone release or exogenous exposure.

Obtain serum TSH with free T4 and free or total T3. Sensitive TSH is the most sensitive outpatient screening test for thyroid hormone excess. Suppressed TSH with elevated free T4 and/or T3 indicates overt thyrotoxicosis; the biochemical pattern alone does not distinguish Graves disease from autonomous nodules, thyroiditis, iodine-associated disease, or exogenous thyroid hormone use. [8][23]

Do not label a patient with low TSH, normal free T4, and elevated T3 as having subclinical hyperthyroidism. Subclinical hyperthyroidism requires both free T4 and free T3 to be normal; isolated T3 elevation with suppressed TSH should prompt evaluation for toxic nodular goiter or early Graves disease. [23]

Use the medication, supplement, pregnancy, and exposure history to direct testing. Specifically identify thyroid hormone ingestion, amiodarone or other iodine exposure, and recent postpartum status, because these point toward etiologies that require different management than thyroid-stimulating autoimmunity. [8]
- Suppressed TSH plus high free T4 and high or normal-high free T3: obtain etiologic testing rather than treating the biochemical syndrome as Graves disease by default. [23]
- Suppressed TSH plus normal free T4 and high free T3: pursue iodine-123 imaging and assess for TRAb and ophthalmopathy. [23]
- Low TSH with normal free T4 and normal free T3: reassess thyroid function tests periodically rather than classify as overt thyrotoxicosis. [23]

*Biochemical patterns that direct the next diagnostic step. [23]*

| TSH and thyroid hormones | Interpretation | Next action |
| --- | --- | --- |
| Low TSH, high free T4, normal or high free T3 | Overt thyrotoxicosis; autonomous hyperfunction is likely when uptake is high. [23] | Obtain iodine-123 uptake and scan; use TRAb and orbitopathy findings to distinguish Graves disease from toxic nodular disease. [23] |
| Low TSH, normal free T4, high free T3 | T3 thyrotoxicosis; not subclinical hyperthyroidism. [23] | Obtain iodine-123 uptake and scan; consider toxic nodular goiter and early Graves disease. [23] |
| Low TSH, normal free T4, normal free T3 | Subclinical hyperthyroidism requires serial biochemical reassessment. [23] | Periodically repeat thyroid function tests. [23] |

## Use TRAb and thyroid imaging to distinguish Graves disease from non-Graves thyrotoxicosis

The diagnosis determines whether antithyroid treatment and definitive thyroid-directed therapy are appropriate.

Order TRAb or TSI when Graves disease is suspected. TSH-receptor antibodies confirm Graves disease, and serial antibody measurements over months to years can help assess response to treatment. Thyroid scintigraphy, TRAb, and thyroid ultrasound are the three principal diagnostic tools used to establish the cause of thyrotoxicosis. [13][24]

Use iodine-123 uptake and scan when antibody testing is unavailable, negative despite persistent clinical suspicion, or when a nodular gland or competing etiologies make the diagnosis uncertain. Diffuse uptake supports Graves disease. High uptake with focal or nodular patterns supports toxic adenoma or toxic multinodular goiter; low uptake redirects evaluation toward thyroiditis, ectopic thyroid hormone production, exogenous thyroid hormone, or iodine-related dysfunction. [3][23][24]

Physical examination remains a useful discriminator but should not substitute for biochemical or imaging confirmation when treatment will be definitive. Ophthalmopathy and positive TRAb favor Graves disease, whereas toxic nodular goiter is generally TRAb-negative and lacks ophthalmopathy. [23]
- Diffuse high uptake: Graves disease is favored. [3][23]
- High uptake with nodularity: evaluate for toxic adenoma or toxic multinodular goiter rather than autoimmune hyperthyroidism. [23]
- Low uptake: do not assume antithyroid drugs will correct the process; investigate thyroiditis, ectopic hormone production, exogenous hormone use, or iodine-associated disease. [23]
- Positive TRAb or TSI: supports Graves disease and provides a marker that can be followed during therapy. [20][24]

*Etiologic patterns in thyrotoxicosis and their management implications. [8][23]*

| Pattern | Likely diagnosis | Management implication |
| --- | --- | --- |
| Diffuse isotope uptake; TRAb-positive; possible ophthalmopathy | Graves disease. [3][23] | Select among antithyroid drugs, radioactive iodine, and thyroidectomy after assessing orbitopathy, pregnancy plans, relapse, and patient goals. [8][12] |
| High uptake with focal or heterogeneous nodular pattern; TRAb-negative; no ophthalmopathy | Toxic adenoma or toxic multinodular goiter. [23] | Treat as autonomous thyroid function rather than Graves disease. [8][23] |
| Low isotope uptake | Thyroiditis, ectopic hormone production, exogenous hormone use, or iodine-related thyrotoxicosis. [23] | Reassess the etiologic branch before initiating Graves-specific definitive therapy. [8][23] |

## Choose antithyroid drugs, radioactive iodine, or thyroidectomy by clinical context

All three established modalities can control Graves hyperthyroidism, but their tradeoffs differ. [8][12]

Use an antithyroid drug, radioactive iodine (RAI), or thyroidectomy as the principal treatment pathway for confirmed Graves disease. Antithyroid drugs are commonly associated with relapse, while RAI has historically been described as a common U.S. treatment choice; thyroidectomy remains an established option. The choice should explicitly account for orbitopathy, reproductive status, likelihood of sustained medical remission, gland anatomy, and preference for thyroid preservation versus definitive treatment. [8][12]

Methimazole is the usual antithyroid agent in nonpregnant patients, but dose matters. Methimazole-associated agranulocytosis was more frequent with an initial 30 mg daily dose than with 15 mg daily, supporting use of the lowest effective starting dose rather than routine high-dose treatment. [5]

Long-term antithyroid therapy is a reasonable alternative to surgery or RAI for patients with persistent TRAb elevation who prefer medical management. Treatment beyond 24 months has been associated with higher remission rates than the traditional approximately 18-month course in contemporary reviews, although definitive therapy remains appropriate when medical therapy is ineffective, not tolerated, or inconsistent with patient goals. [10][11]

If selecting RAI, counsel that biochemical and clinical follow-up is required after treatment. In one cohort, assessment occurred at 1, 3, 6, and 12 months after a single treatment; higher maximal iodine uptake or longer effective half-life was associated with a greater likelihood of one-time cure, whereas older age and positive TRAb or thyroglobulin antibodies were associated with lower likelihood of one-time cure. [15]

Consider thyroidectomy when a definitive option is preferred or when RAI and prolonged drug therapy are unsuitable. Current guidance has generally recommended achieving euthyroidism before surgery to reduce perioperative risk, although evidence supporting a mandatory euthyroid state is described as inconclusive. [19]
- Avoid escalation to methimazole 30 mg daily by default; higher initial dosing has been linked to more agranulocytosis than 15 mg daily. [5]
- For persistent TRAb elevation after a conventional course, discuss long-term antithyroid therapy beyond 24 months as an alternative to RAI or surgery. [11]
- For RAI recipients, plan thyroid function and clinical surveillance rather than assuming one treatment will cure every patient. [15]
- Before thyroidectomy, assess biochemical control and perioperative risk; euthyroidism is guideline-recommended even though the evidentiary basis is not definitive. [19]

*Treatment-selection framework for confirmed Graves disease. [8][10][11][12][19]*

| Treatment path | When it fits | Key tradeoff or action |
| --- | --- | --- |
| Methimazole-based antithyroid therapy | Patients seeking thyroid preservation or a nonprocedural initial approach. [10][12] | Use the lowest effective dose; agranulocytosis was more frequent with initial 30 mg than 15 mg daily. [5] |
| Long-term antithyroid therapy | Persistent TRAb elevation in patients preferring to avoid RAI or surgery. [11] | Therapy beyond 24 months is a reasonable alternative and has been associated with higher remission than a traditional 18-month course. [10][11] |
| Radioactive iodine | Patients selecting definitive nonsurgical treatment without a competing orbitopathy concern. [8][12] | Follow clinically and biochemically after treatment; one-time cure probability varies with uptake, effective half-life, age, and antibody status. [15] |
| Thyroidectomy | Patients requiring or preferring definitive surgical treatment. [12][19] | Guidance generally recommends biochemical preparation to euthyroidism before surgery. [19] |

## Make Graves orbitopathy a treatment-selection determinant

Orbitopathy activity, severity, and dominant phenotype can change the preferred systemic and thyroid-directed approach.

Screen every patient with Graves disease for eye symptoms and signs, then distinguish mild disease from moderate-to-severe active disease and sight-threatening disease. Contemporary EUGOGO and ATA/ETA documents broadly agree on classification, assessment, prevention, and management of mild, inactive, and sight-threatening Graves orbitopathy, but differ materially for moderate-to-severe active disease. [6]

For moderate-to-severe active orbitopathy, ATA/ETA consensus identifies teprotumumab as first-line treatment for virtually all phenotypes, particularly when exophthalmos predominates. The same consensus favors intravenous glucocorticoids when the primary goal is inactivation and resolution of inflammation; intravenous glucocorticoids plus orbital radiotherapy are among preferred approaches when inactivation and correction of eye dysmotility are the goals. [6]

EUGOGO instead identifies intravenous glucocorticoids, with or without mycophenolate, as first-line therapy for moderate-to-severe active disease. This is a genuine treatment-choice controversy; phenotype and therapeutic objective should drive the discussion rather than treating all active orbitopathy as a single entity. [6]

Avoid treating thyroid autonomy and orbitopathy as separate problems. RAI requires caution in patients with moderate-to-severe active orbitopathy, and future guidance may reconsider cautious RAI use only in conjunction with intravenous glucocorticoids, with or without orbital radiotherapy. [6]
- Exophthalmos-predominant, moderate-to-severe active disease: discuss teprotumumab under ATA/ETA consensus. [6]
- Inflammation inactivation as the treatment goal: intravenous glucocorticoids are preferred in ATA/ETA consensus. [6]
- Active disease under EUGOGO guidance: intravenous glucocorticoids with or without mycophenolate are first-line. [6]
- Eye muscle dysmotility requiring both inactivation and correction: consider intravenous glucocorticoids plus orbital radiotherapy among ATA/ETA-preferred approaches. [6]

*Moderate-to-severe active Graves orbitopathy: therapy differs by phenotype and treatment goal. [6]*

| Clinical objective | ATA/ETA consensus emphasis | EUGOGO emphasis |
| --- | --- | --- |
| Predominant exophthalmos | Teprotumumab is first-line, particularly for exophthalmos-predominant disease. [6] | Intravenous glucocorticoids with or without mycophenolate are first-line for active moderate-to-severe disease. [6] |
| Inflammation inactivation | Intravenous glucocorticoids are preferred. [6] | Intravenous glucocorticoids with or without mycophenolate are first-line. [6] |
| Eye dysmotility with active inflammation | Intravenous glucocorticoids plus orbital radiotherapy are among preferred treatments. [6] | Management framework differs; intravenous glucocorticoids with or without mycophenolate remains first-line for active moderate-to-severe disease. [6] |

## Titrate Graves therapy through pregnancy and account for fetal antibody-mediated risk

Maternal biochemical improvement does not eliminate fetal risk from persistent TSH-receptor antibodies.

Reassess antithyroid drug requirement frequently throughout pregnancy. Graves disease may improve during the second and third trimesters, and low doses or discontinuation of antithyroid drugs may be possible in the third trimester when maternal disease activity permits. [2][16]

Do not equate prior definitive therapy or maternal clinical quiescence with absence of fetal risk. Women with current Graves disease or a past Graves history can have fetal thyrotoxicosis because maternal TSH-receptor antibodies cross the placenta. [18]

Use TRAb as both a diagnostic and longitudinal marker in Graves disease; in pregnancy, a current or prior Graves history should trigger consideration of fetal risk from transplacental antibodies even when the maternal thyroid is no longer hyperfunctioning. [18][24]
- Second and third trimester: reassess frequently for a falling antithyroid drug requirement. [2][16]
- Third trimester: consider low-dose treatment or discontinuation only when maternal control allows. [2]
- Current or prior Graves disease: recognize fetal thyrotoxicosis risk from placental passage of maternal TSH-receptor antibodies. [18]

## References
1. Update on the Management of Hyperthyroidism and ... — jamanetwork.com — https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485294
2. Treatment Guidelines for Patients With Hyperthyroidism and ... — jamanetwork.com — https://jamanetwork.com/journals/jama/articlepdf/387402/jama_273_10_038.pdf?resultClick=1
3. Hyperthyroidism — www.acpjournals.org — https://www.acpjournals.org/doi/pdf/10.7326/AITC202004070
4. Hyperthyroidism | Annals of Internal Medicine — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/AITC202004070
5. Antithyroid therapy—best choice of drug and dose — www.nature.com — https://www.nature.com/articles/nrendo.2009.201
6. Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy — www.sciencedirect.com — https://www.sciencedirect.com/org/science/article/pii/S2235080225000996
7. or Non‐Graves' Thyrotoxicosis: A Review for Clinical ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/cen.70192
8. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1530891X20402356
9. Current concepts regarding Graves' orbitopathy - Bartalena — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/joim.13524
10. The evolving therapeutic landscape of Graves’ disease in adults: present and future — www.sciencedirect.com — https://www.sciencedirect.com/org/science/article/pii/S2235080225000650
11. Management Aspects of Medical Therapy in Graves Disease — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1530891X2400870X
12. British Thyroid Association Survey of Graves' Disease ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/cen.15266
13. Diagnostic Options in Graves' or Non‐Graves' Thyrotoxicosis — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111/cen.70192
14. Evaluation of YouTube As A Source For Graves' Disease ... — aao-hnsfjournals.onlinelibrary.wiley.com — https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/full/10.1002/oto2.118
15. Analysis of 131I therapy and correlation factors... : Nuclear Medicine Communications — journals.lww.com — https://journals.lww.com/00006231-201201000-00014
16. Thyroid Disease in Pregnancy — journals.lww.com — https://journals.lww.com/postgradobgyn/fulltext/2006/07150/thyroid_disease_in_pregnancy.1.aspx?Ppt=Article%7Cpostgradobgyn%3A2006%3A07150%3A00001%7C%7C
17. Brief Overview of the Role of Nuclear Medicine in... — journals.lww.com — https://journals.lww.com/cmii/fulltext/2018/16040/brief_overview_of_the_role_of_nuclear_medicine_in.3.aspx
18. Fetal Thyrotoxicosis due to Maternal TSH Receptor... : Hormone Research in Paediatrics — journals.lww.com — https://journals.lww.com/01436844-202497020-00012
19. Research plan/Protocol for HRO: Further use of biological ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/03/NCT06963203/Prot_SAP_000.pdf
20. Tests for people with confirmed thyrotoxicosis - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/n/niceng145er8
21. Thyroid disease: assessment and management — www.nice.org.uk — https://www.nice.org.uk/guidance/ng145/documents/evidence-review-8
22. A SURVEY OF CLINICAL PRACTICE PATTERNS IN MANAGEMENT OF GRAVES DISEASE IN THE MIDDLE EAST AND NORTH AFRICA - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/27967219
23. Cleveland Clinic Journal of Medicine Approach to a low TSH level: Patience is a virtue — www.ccjm.org — https://www.ccjm.org/content/ccjom/77/11/803.full.pdf
24. Pediatric Thyroid Function Tests |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/pediatric-thyroid-function

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.